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BRIEF COMMUNICATION
Noonan syndrome (NS) is an autosomal domi-
nant disorder with characteristic facies, short
stature, skeletal anomalies, and defects of the heart.
NS was first reported by Jacqueline Noonan in
1963;1 however, definite clinical diagnosis2 of
this condition is difficult because it is clinically
heterogeneous and the phenotypic expression is
highly variable and changes with age.3 In 2001,
Tartaglia et al identified the protein-tyrosine phos-
phatase, nonreceptor-type 11 (PTPN11, MIM#
176876), which encodes SHP-2, as the first NS
gene.4 Missense mutations in PTPN11 accounted
for 31–60% of cases in previous reports.5 These mu-
tations were demonstrated to be gain-of-function
changes that resulted in excessive SHP-2 activity.
In order to pinpoint the causative gene in NS 
in Taiwanese children, we carried out mutation
screening of the PTPN11 gene in 34 NS 
patients.
Methods
The study protocol was approved by the Medical
Ethics and Human Clinical Trials Committee of
Chang Gung Memorial Hospital. After obtaining
informed parental consent, unrelated Taiwanese
children with NS were enrolled. The children
were screened for mutations in the PTPN11 gene.
NS was diagnosed according to major criteria
(typical facial findings, cardiac defects, pterygium
colli) and minor criteria (short stature, psychomotor
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retardation or speech delay, bleeding diathesis,
family history of NS, and other additional fea-
tures).5 NS was sporadic in 30 patients and 
familial in four.
Genomic DNA samples were extracted from
peripheral whole blood of all patients using the
standard procedure. For each patient, exons 1–15
of the PTPN11 gene were individually amplified
by polymerase chain reaction (PCR) using 15
sets of primer sequences derived from published
data.6,7 The PCR products were then purified using
the High Purified PCR Product Purification Kit
(Roche Molecular Biochemicals, Mannheim,
Germany) and directly sequenced using a cycle
sequencing method.
Results
There were 34 unrelated children with NS, 
including 20 males and 14 females, with a mean
age of 9.06 ± 5.03 years (range, 1.79–18.33 years).
A total of 10 different PTPN11 mutations, in-
cluding one novel missense mutation (855T > G,
F285L) (Figure), were identified in 13 (38%) 
patients (Table 1). All 10 mutations were het-
erozygous missense mutations clustered in exon
3 encoding the N-SH2 domain (n = 6), in exon 4
(n = 2) encoding the C-SH2 domain, in exon 
8 (n = 2) or in exon 13 (n = 3) encoding the PTP
domain. Mutations were identified in three famil-
ial cases with autosomal dominant inheritance.
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Figure.Mutation analysis of the PTPN11 gene in Taiwanese children with Noonan syndrome. (A) Sequencing chromatogram
of one novel PTPN11 mutation (855T>G, F285L). (B) Distribution of the missense mutations identified in the PTPN11 gene
in this study.
Table 1. PTPN11 mutations in 13 unrelated Taiwanese patients with Noonan syndrome
Case Occurrence Exon Nucleotide substitution Amino acid substitution Functional domain Remark
1 Sporadic 3 184A > G Y62D N-SH2
2 Sporadic 3 188A > G Y63C N-SH2
3 Sporadic 3 188A > G Y63C N-SH2
4 Familial 3 214G > T A72S N-SH2
5 Sporadic 3 218C > T T73I N-SH2
6 Sporadic 3 317A > C D106A N-SH2
7 Sporadic 4 417G > C E139D C-SH2
8 Familial 4 417G > C E139D C-SH2
9 Sporadic 8 855T > G F285L PTP Novel
10 Sporadic 8 922A > G N308D PTP
11 Sporadic 13 1493G > T R498L PTP
12 Familial 13 1510A > G M504V PTP
13 Sporadic 13 1510A > G M504V PTP
This novel mutation was not found in 100 
normal individuals (i.e. 200 normal chromo-
somes). The most frequently reported presenta-
tions of mutation-positive and -negative NS were
short stature (83% vs. 100%), learning disabili-
ties (82% vs. 71%), low hair line (77% vs. 71%),
epicanthus (69% vs. 48%), webbed neck (46%
vs. 71%), down-slanting palpebral fissures (54%
vs. 62%), cubitus valgus (38% vs. 71%), thorax
deformity (30% vs. 43%), ptosis (23% vs. 43%),
hearing impairment (10% vs. 19%), cryptorchi-
dism (17% vs. 47%), and pulmonary stenosis
(23% vs. 45%). However, the prevalence of these
features was not significantly different between
the two groups. Atrial and/or ventricular defects
were more common in the PTPN11 mutations
group than in the non-mutation group (69% vs.
33%, p = 0.05).
Discussion
This study is the first report of 10 PTPN11 muta-
tions in Taiwanese patients with NS. One of these
was a novel mutation (855T > G, F285L), while
the other nine have previously been identified in
patients from other countries.4,7 The novel muta-
tion site was similar to that of two previously re-
ported mutations (853T > C, F285L; 854T > C,
F285S).6,7 These findings provide further evidence
that PTPN11 mutations are responsible for the
development of NS in Taiwanese.
To date, 41 different mutations have been iden-
tified in 255 individuals with NS. With the excep-
tion of two trinucleotide deletions,8,9 the causative
mutations are all missense mutations.10 The ma-
jority of PTPN11 mutations are recurrent and
clustered in exon 3 encoding the N-SH2 domain
or in exons 8 and 13 encoding the PTP domain.
Shp-2, encoded by the PTPN11 gene, has two 
N-terminal SH2 domains (N-SH2 and C-SH2), 
a classic PTP domain and a C-terminal tail. SH2
domains (particularly N-SH2) regulate PTP activ-
ity. In the basal state, Shp-2 is largely inactive 
because of mutual allosteric inhibition due to the
“backside loop” of N-SH2 being inserted into
the catalytic cleft.11 Missense mutations in exons
3 and 8, within subregions of the N-SH2 and PTP
domains, disrupt the intramolecular inhibition
and lead to a conformational change resulting in
a constitutively active form.
Mutations in PTPN11 accounted for approxi-
mately 38% of NS cases in this study. This muta-
tion detection rate is similar to findings in previous
reports, with an average of 42% (255/606), rang-
ing between 31% and 60% (Table 2).4–7,12–15 The
accumulated data suggest that PTPN11 mutation-
negative NS tend to exhibit fewer or mild clinical
features of NS, even though a relatively large per-
centage of mutation-negative NS patients appear
clinically indistinguishable from mutation-positive
NS patients.10 In this study, atrial and/or ventric-
ular defects were more common in the mutation-
positive group than in the mutation-negative group
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Table 2. Summary of reported mutation rate of PTPN11 gene in cases of Noonan syndrome to date
Authors Year of publication Country of publication Frequency, n (%)
Targaglia et al4 2001 USA 11/22 (50)
Targaglia et al7 2002 USA 54/119 (45)
Musante et al12 2002 Germany 32/96 (33)
Maheshwari et al13 2002 USA 5/16 (31)
Kosaki et al6 2002 Japan 7/21 (33)
Sarkozy et al14 2003 Italy 23/71 (32)
Zenker et al5 2004 Germany 34/57 (60)
Jongmans et al15 2005 The Netherlands 76/170 (45)
Hung et al (this study) 2007 Taiwan 13/34 (38)
Total 255/606 (42)
(69% vs. 33%, p=0.05), a finding compatible with
the results of Sarkozy et al.14
In conclusion, this study documented the
PTPN11 mutations and their phenotypic correla-
tions in a series of Taiwanese patients with NS.
Most patients without PTPN11 mutation appeared
clinically indistinguishable from typical PTPN11
mutation-positive patients. Molecular analysis of
the intracellular signaling mechanism of SHP-2
with clinical findings will serve to clarify the
pathogenesis of NS.
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